Drug – bio-affecting and body treating compositions – Lymphokine – Interleukin
Patent
1995-03-28
1998-03-10
Smith, Lynette F.
Drug, bio-affecting and body treating compositions
Lymphokine
Interleukin
424 851, 424 854, A61K 4505, A61K 3821
Patent
active
057258511
ABSTRACT:
D-factor, growth hormone, IL-1, and tumor necrosis factors are employed alone or in combination as synergistic cytoprotective agents for patients exposed to toxic doses of ionizing radiation and/or chemotherapy. Synergistic cytoprotective regimens are provided. Use of D-factor, growth hormone, tumor necrosis factors, and/or IL-1, alone or in synergistic combination, is disclosed for the prevention and treatment of alopecia.
REFERENCES:
patent: 4321832 (1982-03-01), Runyan
patent: 4861587 (1989-08-01), Urbaschek et al.
patent: 4985241 (1991-01-01), Zimmerman et al.
patent: 5202119 (1993-04-01), Clark et al.
patent: 5370870 (1994-12-01), Wong
Abe et al., J. Biol. Chem. 264 (15):8941-8945 (May 25, 1989) "Macrophage Differentiation Inducing Factor from Human Monocyclic Cells is Equivalent to Murine Leukemia Inhibitory Factor".
Carswell et al., Proc. Natl. Acad. Sci. U.S.A., 72(9): 3666-3670 (Sep., 1975) An Endotoxin-Induced Serum Factor that Causes Necrosis of Tumors.
Clark et al., J. Cell Biochem. Suppl., 12A:40 (Jan., 1988) Interplay of Reactive Oxygen Species and Tumor Necrosis Factor in Tissue injury.
Cross et al., J. Exp. Med., 169:2021-2027 (Jun., 1989) Pretreatment with Recombinant Murine Tumor Necrosis Factor .alpha./Cachectin and Murine Interleukin 1 .alpha. Protects Mice from Lethal Bacterial Infection.
Fukada et al., PNAS 82:8795-8799 (Dec., 1985) Purification and Partial Characterization of a Cholingergic Neuronal Differentiation Factor.
Gearing, et al., Nucleic Acids Res., 16:9857 (1988) Complete Sequence of Murine Myeloid Leukaemia Inhibitory Facotr (LIF).
Gough et al., Proc. Natl. Acad. Sci. U.S.A., 85:2623-2627 (Apr., 1988) Molecular Cloning and Expression of the Human Homologue of the Murine Gene Encoding Myeloid Leukemia-Inhibitory Factor.
Hahn et al., Proc. Natl. Acad. Sci. U.S.A., 82:3814-3818 (Jun., 1985) Use of Monoclonal Antibodies to a Human Cytotoxin for its Isolation and for Examining the Self-Induction of Resistance to this Protein.
Hilton et al., Anal. Biochem. 173:359-367 (1988) Purification of a Murine Leukemia Inhibitory Factor from Krebs Ascites Cells.
Holtman et al., J. Immunol., 139:1161-1167 (Aug. 15, 1987) Down Regulation of the Receptors for Tumor Necrosis Factor by Interleukin 1 and 4.beta.-Phorbol-12-Myistate-13-Acetate.sup.1.
Hozumi, Advances in Cancer Research 38:121-169 (1983) Fundamentals of Chemotherapy of Myeloid Leukemia by Induction of Leukemia Cell Differentiation.
Hussein et al., Science, 249:1564-1566 (Sep., 1990) Protection from Chemotherapy-Induced Alopecia in a Rat Model.
Jacob et al., Nature, 331:356-358 (Jan., 1988) Tumor Necrosis Factor-.alpha. in Murine Autoimmune `Lupus` Nephritis.
Lowe et al., DNA, 8(5):351-359 (1989) Genomic Cloning and Heterlogous Expression of Human Differentiation-Stimulating Factor.
March et al., Nature, 315:641-647 (Jun., 1985) Cloning, Sequence and Expression of Two Distinct Human Interleukin-1 Complementary DNAs
Moreau et al., Nature 336:690-692 (Dec. 15, 1988) Leukemia Inhibitory Factor is Identical to the Myeloid Growth Factor Human Interleukin for DA Cells.
Mori et al., Biochem. Biophys. Res. Com. 160(3):1085-1092 (May, 1989) Purification of a Lipoprotein Lipase-Inhibiting Protein Produced by a Melanoma Cell Line Associated with Cancer Cachexia.
Neta et al., Fed. Proc., 46:1200 (abstract) (Jan., 1987) Comparison of the In Vivo Effects of rIL-1 in Radioprotection, Induction of CSF and of Acute Phase Reactants.
Neta et al., J. Immunol., 136(7):2483-2485 (Apr. 1, 1986) Interleukin 1 is a Radioprotector.sup.1.
Neta et al., J. Immunol., 140:108-111 (Jan. 1, 1988) Interdependence of the Radioprotective Effects of Human Recombinant Interleukin 1.alpha., Tumor Necrosis Factor .alpha., Granulocyte Colony-Stimulating Factor, and Murine Recombinant Granulocyte-Macrophage Colony-Stimulating Factor.sup.1.
Neta et al., Blood, 72(3):1093-1094 (Sep., 1988) Cytokins in Therapy of Radiation Injury.
Neta et al., Lymphokine Research 5(1):S105-S110 (1986) Cytokines n Radioprotection Comparison of the Radioprotective Effects of IL-1 to IL-2, GM-CSF and IFN.sub..gamma..
Palladino et al., Intl. J. Radiat. Biol., 41:183-191 (1982) .gamma.-Irradiation-Induced Mortality: Protective Effect of Protease Inhibitors in Chickens and Mice.
Schutze et al., J. Immunol., 140:3000-3005 (May 1, 1988) Tumor Necrosis Factor-Induced Changes of Gene Expression in U937 Cells.
Slordahl et al., Eur. J. Hematology, 43:428-434 (1989) Radioprotection by Murine and Human Tumor-Necrosis Factor: Dose-Dependent Effects on Hematopoiesis in the Mouse.
Sugarman et al., Science, 230:943-945 (Nov. 22, 1985) Recombinant Human Tumor Necrosis Factor-.alpha.: Effects on Proliferation of Norman and Transformed Cells in Vitro.
Sullivan et al., Infect. and Immunity, 56(7):1722-1729 (Jul., 1988) Inhibition of the Inflammatory Action of Interleukin-1 and Tumor Necrosis Factor (Alpha) on Neutrophil Function by Pentoxifylline.
Tiegs et al., Biochem. Pharmacol., 38(4):627-631 (1989) Tumor Necrosis Factor is a Terminal Mediator in Galactosamine/Endotoxin-Induced Hepatitis in Mice.
Urbaschek et al., Lymphokine Res., 6(3)179-186 (1987) Tumor Necrosis Factor Induced Stimulation of Granulopoiesis and Radioprotection.
Wallach, J. Immunol., 132:2464-2469 (May, 1984) Preparations of Lymphotoxin Induce Resistance to their Own Cytotoxic Effect.sup.1.
Wong et al., Science 242:941-944 (Nov., 1988) Induction of Manganous Superoxide Dismutase by Tumor Necrosis Factor: Possible Protective Mechanism.
Wong et al., Cell, 58:923-931 (Sep. 8, 1989) Manganous Superoxide Dismutase is Essential for Cellular Resistance to Cytotoxicity of Tumor Necrosis Factor.
Yamamori et al., Science, 246:1412-1416 (Dec. 15, 1989) The Cholinergic Neuronal Differentiation Factor from Heart Cells is Identical to Leukemia Inhibitory Factor.
Yuhas et al., J. Natl. Cancer Inst., 42(2):331-335 (Feb., 1969) Differential Chemoprotectin of Normal and Malignant Tissues.sup.1,2,3.
Goeddel David V.
Wong Grace H.W.
Genentech Inc.
Smith Lynette F.
LandOfFree
Method and compositions for treating injury does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method and compositions for treating injury, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method and compositions for treating injury will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-137095